Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is a company with a positive outlook for the future due to recent developments such as securing a 10-year agreement with BARDA, an expanding wound care portfolio, and exiting its stabilization phase with a projected revenue growth of 12% to 19%. While the company's current focus is on the US region, it has potential for international growth in the future and is backed by strong government relationships and validation for its innovative burn treatment device. Some risk factors to consider are potential clinical/regulatory and financial risks, but the company's recent debt refinancing and progress in clinical trials provide confidence in its growth trajectory.

Bears say

AVITA Medical is currently dependent on government contracts to support the sales of their product, with minimal revenue coming from commercial sales. The company's single product, RECELL, has shown promising clinical results, but it remains to be seen if it can translate into sustained revenue growth beyond episodic government support. The recent updates and clinical data flow support the potential of Cohealyx as a complementary solution within AVITA's treatment ecosystem. However, the impact of reimbursement friction and high operating expenses have resulted in a significant net loss for the company. Until the company can demonstrate sustained revenue growth and improved financials, it is prudent to maintain a negative outlook on AVITA Medical's stock.

RCEL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Strong Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.